Directing vaccine immune responses to mucosa by nanosized particulate carriers encapsulating NOD ligands

Biomaterials

Volumn 75, Issue , 2016, Pages 327-339

  Pavot, Vincent ^a   Climent, Nuria ^b   Rochereau, Nicolas ^c   Garcia, Felipe ^b   Genin, Christian ^c   Tiraby, Gérard ^d   Vernejoul, Fabienne ^d   Perouzel, Eric ^d   Lioux, Thierry ^d   Verrier, Bernard ^a   Paul, Stéphane ^c  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITÉ JEAN MONNET   (France)

^d Zone industrielle de Montaudran   (France)

Author keywords

Adjuvant; Dendritic cells; Mucosa; NOD ligands; PLA nanoparticles; Vaccine formulations

Indexed keywords

ANTIGENS; IMMUNE SYSTEM; MOLECULES; NANOPARTICLES; VACCINES;

ADJUVANT; BIODEGRADABLE NANOPARTICLE; DENDRITIC CELLS; INFECTIOUS DISEASE; MUCOSA; MUCOSAL IMMUNE RESPONSE; NANO-SIZED PARTICULATES; NOD-LIKE RECEPTORS;

LIGANDS;

6 O STEAROYL N GLYCOLYL MURABUTIDE; ANTIGEN P24; GAG PROTEIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIGAND; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NANOPARTICLE; POLYLACTIC ACID; RANTES; TETRADECANOYL DELTA GLUTAMYL LEVO MESO LANTHIONYL DEXTRO ALANINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CARD15 PROTEIN, MOUSE; CARD4 PROTEIN, MOUSE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CYTOKINE; DRUG CARRIER; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LACTIC ACID; POLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; AUTOPHAGY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG POTENCY; DRUG UPTAKE; EPITHELIUM CELL; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; MUCOSAL IMMUNITY; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; VAGINAL LAVAGE; ZETA POTENTIAL; ANIMAL; B LYMPHOCYTE; BAGG ALBINO MOUSE; CHEMISTRY; ENDOCYTOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; METABOLISM; MUCOSA; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION; VAGINA;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; AIDS VACCINES; ANIMALS; B-LYMPHOCYTES; CELL PROLIFERATION; CYTOKINES; DENDRITIC CELLS; DRUG CARRIERS; ENDOCYTOSIS; FEMALE; HIV INFECTIONS; HUMANS; IMMUNITY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; LACTIC ACID; LIGANDS; MICE, INBRED BALB C; MUCOUS MEMBRANE; NANOPARTICLES; NOD1 SIGNALING ADAPTOR PROTEIN; NOD2 SIGNALING ADAPTOR PROTEIN; PARTICLE SIZE; POLYMERS; VACCINATION; VAGINA;

EID: 84946426408     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.10.034     Document Type: Article

References (60)

1. Holmgren J., Svennerholm A.M. Vaccines against mucosal infections. Curr. Opin. Immunol. 2012, 24:343-353.
2. Belyakov I.M., Ahlers J.D. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?. J. Immunol. 2009, 183:6883-6892.
3. Czerkinsky C., Holmgren J. Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. Curr. Top. Microbiol. Immunol. 2012, 354:1-18.
4. Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat. Rev. Immunol. 2012, 12:592-605.
5. Pavot V., Rochereau N., Genin C., Verrier B., Paul S. New insights in mucosal vaccine development. Vaccine 2012, 30:142-154.
6. Pavot V., Rochereau N., Lawrence P., Girard M.P., Genin C., Verrier B., et al. Recent progress in HIV vaccines inducing mucosal immune responses. AIDS 2014, 28:1701-1718.
7. Lawson L.B., Norton E.B., Clements J.D. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Curr. Opin. Immunol. 2011, 23:414-420.
8. Zhao L., Seth A., Wibowo N., Zhao C.X., Mitter N., Yu C., et al. Nanoparticle vaccines. Vaccine 2014, 32:327-337.
9. Smith J.D., Morton L.D., Ulery B.D. Nanoparticles as synthetic vaccines. Curr. Opin. Biotechnol. 2015, 34:217-224.
10. Primard C., Rochereau N., Luciani E., Genin C., Delair T., Paul S., et al. Traffic of poly(lactic acid) nanoparticulate vaccine vehicle from intestinal mucus to sub-epithelial immune competent cells. Biomaterials 2010, 31:6060-6068.
11. Sharma R., Agrawal U., Mody N., Vyas S.P. Polymer nanotechnology based approaches in mucosal vaccine delivery: challenges and opportunities. Biotechnol. Adv. 2015, 33:64-79.
12. Pavot V., Berthet M., Resseguier J., Legaz S., Handke N., Gilbert S.C., et al. Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery. Nanomedicine 2014, 9:2703-2718.
13. Sharma R., Agrawal U., Mody N., Vyas S.P. Polymer nanotechnology based approaches in mucosal vaccine delivery: challenges and opportunities. Biotechnol. Adv. 2014, 33:64-79.
14. Athanasiou K.A., Niederauer G.G., Agrawal C.M. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials 1996, 17:93-102.
15. Zhu Q., Talton J., Zhang G., Cunningham T., Wang Z., Waters R.C., et al. Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nat. Med. 2012, 18:1291-1296.
16. Kasturi S.P., Skountzou I., Albrecht R.A., Koutsonanos D., Hua T., Nakaya H.I., et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011, 470:543-547.
17. Motta V., Soares F., Sun T., Philpott D.J. NOD-like receptors: versatile cytosolic sentinels. Physiol. Rev. 2015, 95:149-178.
18. Maisonneuve C., Bertholet S., Philpott D.J., De Gregorio E. Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:12294-12299.
19. Pavot V., Rochereau N., Resseguier J., Gutjahr A., Genin C., Tiraby G., et al. Cutting edge: New chimeric NOD2/TLR2 adjuvant drastically increases vaccine immunogenicity. J. Immunol. 2014, 193:5781-5785.
20. Girardin S.E., Boneca I.G., Carneiro L.A., Antignac A., Jehanno M., Viala J., et al. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 2003, 300:1584-1587.
21. Girardin S.E., Boneca I.G., Viala J., Chamaillard M., Labigne A., Thomas G., et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 2003, 278:8869-8872.
22. Franchi L., Warner N., Viani K., Nunez G. Function of Nod-like receptors in microbial recognition and host defense. Immunol. Rev. 2009, 227:106-128.
23. Ogura Y., Inohara N., Benito A., Chen F.F., Yamaoka S., Nunez G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J. Biol. Chem. 2001, 276:4812-4818.
24. Ogura Y., Lala S., Xin W., Smith E., Dowds T.A., Chen F.F., et al. Expression of NOD2 in paneth cells: a possible link to Crohn's ileitis. Gut 2003, 52:1591-1597.
25. Claes A.K., Zhou J.Y., Philpott D.J. NOD-Like Receptors: Guardians of Intestinal Mucosal Barriers. Physiology 2015, 30:241-250.
26. Pavot V., Rochereau N., Primard C., Genin C., Perouzel E., Lioux T., et al. Encapsulation of Nod1 and Nod2 receptor ligands into poly(lactic acid) nanoparticles potentiates their immune properties. J. Control. Release Off. J. Control. Release Soc. 2013, 167:60-67.
27. Wischke C., Mathew S., Roch T., Frentsch M., Lendlein A. Potential of NOD receptor ligands as immunomodulators in particulate vaccine carriers. J. Control. Release Off. J. Control. Release Soc. 2012, 164:299-306.
28. Norton E.B., Lawson L.B., Mahdi Z., Freytag L.C., Clements J.D. The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens. Infect. Immun. 2012, 80:2426-2435.
29. Marrack P., McKee A.S., Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 2009, 9:287-293.
30. Ataman-Onal Y., Munier S., Ganee A., Terrat C., Durand P.Y., Battail N., et al. Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models. J. Control. Release Off. J. Control. Release Soc. 2006, 112:175-185.
31. Kim G.G., Donnenberg V.S., Donnenberg A.D., Gooding W., Whiteside T.L. A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay. J. Immunol. Methods 2007, 325:51-66.
32. Soler E., Parez N., Passet B., Dubuquoy C., Riffault S., Pillot M., et al. Recombinant rotavirus inner core proteins produced in the milk of transgenic rabbits confer a high level of protection after intrarectal delivery. Vaccine 2007, 25:6373-6380.
33. Holmgren J., Czerkinsky C., Eriksson K., Mharandi A. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 2003, 21(suppl. 2):S89-S95.
34. Lu X., Clements J.D., Katz J.M. Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine. Vaccine 2002, 20:1019-1029.
35. Guilliams M., Ginhoux F., Jakubzick C., Naik S.H., Onai N., Schraml B.U., et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat. Rev. Immunol. 2014, 14:571-578.
36. de Saint-Vis B., Vincent J., Vandenabeele S., Vanbervliet B., Pin J.J., Ait-Yahia S., et al. A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment. Immunity 1998, 9:325-336.
37. Ahmadi T., Flies A., Efebera Y., Sherr D.H. CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides. Immunology 2008, 124:129-140.
38. Cooney R., Baker J., Brain O., Danis B., Pichulik T., Allan P., et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat. Med. 2010, 16:90-97.
39. Hsu Y.M., Zhang Y., You Y., Wang D., Li H., Duramad O., et al. The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. Nat. Immunol. 2007, 8:198-205.
40. Bystry R.S., Aluvihare V., Welch K.A., Kallikourdis M., Betz A.G. B cells and professional APCs recruit regulatory T cells via CCL4. Nat. Immunol. 2001, 2:1126-1132.
41. Schall T.J., Bacon K., Camp R.D., Kaspari J.W., Goeddel D.V. Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. J. Exp. Med. 1993, 177:1821-1826.
42. Taub D.D., Conlon K., Lloyd A.R., Oppenheim J.J., Kelvin D.J. Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta. Science 1993, 260:355-358.
43. Castellino F., Huang A.Y., Altan-Bonnet G., Stoll S., Scheinecker C., Germain R.N. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 2006, 440:890-895.
44. Levy J.A. The unexpected pleiotropic activities of RANTES. J. Immunol. 2009, 182:3945-3946.
45. Lillard J.W., Boyaka P.N., Taub D.D., McGhee J.R. RANTES potentiates antigen-specific mucosal immune responses. J. Immunol. 2001, 166:162-169.
46. Sakthivel S.K., Singh U.P., Singh S., Taub D.D., Igietseme J.U., Lillard J.W. CCL5 regulation of mucosal chlamydial immunity and infection. BMC Microbiol. 2008, 8:136.
47. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 2006, 6:148-158.
48. Kozlowski P.A., Williams S.B., Lynch R.M., Flanigan T.P., Patterson R.R., Cu-Uvin S., et al. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J. Immunol. 2002, 169:566-574.
49. Staats H.F., Montgomery S.P., Palker T.J. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. AIDS Res. Hum. Retrovir. 1997, 13:945-952.
50. Bansal V., Kumar M., Dalela M., Brahmne H.G., Singh H. Evaluation of synergistic effect of biodegradable polymeric nanoparticles and aluminum based adjuvant for improving vaccine efficacy. Int. J. Pharm. 2014, 471:377-384.
51. Ueno H., Banchereau J., Vinuesa C.G. Pathophysiology of T follicular helper cells in humans and mice. Nat. Immunol. 2015, 16:142-152.
52. Li Z., Palaniyandi S., Zeng R., Tuo W., Roopenian D.C., Zhu X. Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:4388-4393.
53. Kim Y.G., Kamada N., Shaw M.H., Warner N., Chen G.Y., Franchi L., et al. The Nod2 sensor promotes intestinal pathogen eradication via the chemokine CCL2-dependent recruitment of inflammatory monocytes. Immunity 2011, 34:769-780.
54. Ito T., Tanabe H., Ayabe T., Ishikawa C., Inaba Y., Maemoto A., et al. Paneth cells regulate both chemotaxis of immature dendritic cells and cytokine production from epithelial cells. Tohoku J. Exp. Med. 2012, 227:39-48.
55. Campeau J.L., Salim S.Y., Albert E.J., Hotte N., Madsen K.L. Intestinal epithelial cells modulate antigen-presenting cell responses to bacterial DNA. Infect. Immun. 2012, 80:2632-2644.
56. Mulder D.J., Pooni A., Mak N., Hurlbut D.J., Basta S., Justinich C.J. Antigen presentation and MHC class II expression by human esophageal epithelial cells: role in eosinophilic esophagitis. Am. J. Pathol. 2011, 178:744-753.
57. Bergquist C., Johansson E.L., Lagergard T., Holmgren J., Rudin A. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect. Immun. 1997, 65:2676-2684.
58. Jackson E.M., Herbst-Kralovetz M.M. Intranasal vaccination with murabutide enhances humoral and mucosal immune responses to a virus-like particle vaccine. PLoS One 2012, 7:e41529.
59. Balmelli C., Roden R., Potts A., Schiller J., De Grandi P., Nardelli-Haefliger D. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J. Virol. 1998, 72:8220-8229.
60. Janakova L., Bakke H., Haugen I.L., Berstad A.K., Hoiby E.A., Aaberge I.S., et al. Influence of intravenous anesthesia on mucosal and systemic antibody responses to nasal vaccines. Infect. Immun. 2002, 70:5479-5484.